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SYNTHESIS OF 5-SUBSTITUTED 2’-DEOXYURIDINE 
ANALOGUES AND EVALUATION OF THEIR ANTIVIRAL 
ACTIVITY 
A small series of 5-(hetero)aryl-modified nucleoside phosphonates was 
synthesized via an 8-step procedure including a Wittig reaction and Suzuki-
Miyaura coupling. An unanticipated anomerisation during phosphonate 
deprotection allowed us to isolate both anomers of the 5-substituted 2’-deoxy-
uridine phosphonates and assess their antiviral activity against a broad panel of 
viruses. 
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Introduction 
 
Antiviral drugs have become crucial in the management of several viral infections, 
including human HSV, HIV, HBV, HCV and cytomegalovirus (HCMV) infections. 
Prominent among these drugs are nucleoside analogues, which can act as potent 
antiviral agents owing to their ability to inhibit viral polymerases.
1
 Many publications 
have appeared on the synthesis and antiviral activity of 5-modified 2’-deoxyuridine 
analogues. Several substituents have been introduced at C-5, including alkoxymethyl 
groups,
2
 azoles
3
 and alkyloximes.
3
 Several analogues proved moderately to highly 
active against HSV. These results showed that modification at position 5 of 2’-
deoxyuridine represents an interesting approach in the search for new anti-herpes 
agents. However, relatively few examples of 5-(hetero)aryl-modified nucleosides with 
promising antiviral activity have been reported.
 4
 This may be due to the fact that these 
nucleosides are not efficiently converted into their triphosphate form. The first step in 
this process, the phosphorylation of the nucleoside analogue into its 5’-monophosphate 
counterpart by nucleoside kinases, is often rate-limiting in the conversion to the active 
metabolite. One way to overcome this bottleneck is to devise prodrugs that are capable 
of delivering the nucleoside monophosphate intracellularly.
5,6
 Another approach to 
bypass the first phosphorylation step is to use phosphonate analogues, that, after 
intracellular conversion into their corresponding diphosphophosphonate forms, can 
exhibit antiviral activities. This led us to investigate a small series of 2’-deoxyuridine 
analogues that combine different aromatic substituents at position 5 of the base with a 
5’-methylene phosphonate group.  
Results and discussion 
 
The synthesis of a series of 5-(hetero)aryl-modified nucleoside phosphonates 
started from 3’-O-tert-butyldimethylsilyl-2’-deoxy-β-D-uridine7 and is depicted in 
Scheme 1. Conversion of nucleoside 6 to the vinylic phosphonate 7 was accomplished 
following the two-step procedure described by Cosyn et al.
8
 Catalytic hydrogenation of 
7 in the presence of Pd/C afforded phosphonate 8 which was selectively brominated at 
C-5 of the pyrimidine moiety using N-bromosuccinimide in DMF.
9
 Palladium-catalyzed 
cross-coupling with four commercial aryl and heteroaryl boronic acids gave access to 
10-13.
10
 After removing the silyl protecting group, deprotection of the phosphonate 
esters was performed using TMSBr in CH2Cl2. Concomitant anomerisation during this 
last step resulted for each analogue in a 2:1 mixture of the α- and β-isomer, which could 
be separated using RP-HPLC. Stereochemical assignment of compound 1a was based 
on the results of a ROESY experiment (Figure 3). A clear rOe contact between H-4’ and 
H-2’b (proton down) and a much weaker interaction between H-6 and H-2’b proved that 
H-4’ and H-6 were not positioned at the same side of the furanose ring. The β-
configuration of the nucleobase was further established by the presence of a strong 
interaction between H-6 and H-5’a,b.  
In an effort to synthesize the non-modified 2’-deoxyuridine-5’-phosphonate 
analogue, compound 8 was successively treated with a 1M TBAF solution in THF and 
TMSBr in CH2Cl2 (Scheme 2). In this case, attempts to separate the anomeric mixture 
using flash chromatography and RP-HPLC were unsuccessful. To avoid the 
anomerisation issue, we attempted to deprotect 18 in the presence of TMSBr under 
different reaction conditions. Following the reaction via 
31
P NMR, it was observed that 
anomerisation started immediately after addition of TMSBr. We learned by attempts at 
different temperatures that no reaction occurred under -20 °C, and that anomerisation 
started simultaneously with the phosphonate hydrolysis, even at low temperature. Also 
the addition of an acid scavenger (e.g., (trimethylsilyl)acetamide or 2,6-lutidine) could 
not prevent anomerisation.
11
 
 
All compounds were evaluated for their antiviral activity against a broad panel of 
viruses including HSV-1 (KOS), HSV-2 (G), vaccinia virus (VV), vesicular stomatitis 
virus (VSV), thymidine kinase deficient HSV-1 TK
-
 (KOS ACV
r
),
 
HCMV and VZV in 
HEL (human embryonic lung) cell cultures; and HIV-1 (IIIB) and HIV-2 (ROD) in 
human T-lymphocyte (CEM) cell cultures. The activities of the compounds were 
compared with reference antiviral drugs: brivudin, cidofovir, acyclovir and ganciclovir.  
None of the tested compounds showed toxicity to any of the tested cell lines. 
However, the final compounds 1a-4a and 1b-4b failed to show antiviral activity against 
HSV-1, HSV-2, VV, VSV, HSV-1 TK
-
 and different VZV strains. Also in the human T-
lymphocyte (CEM) cell cultures, none of these compounds showed activity against 
HIV-1 or HIV-2. Very weak antiviral activity was observed for the β-analogue 3a and 
the α-analogue 2b against HCMV Davies and HCMV AD-169, respectively, while 
compounds 2a and 4a showed weak activity against both HCMV strains (Table 1). The 
most active compound of this series, analogue 2a, was at least 6 or 50 times less active 
than ganciclovir and cidofovir, respectively. The lack of biological activity of these 
derivatives might be attributed to several features, including 1) their inability to diffuse 
through the cell membrane; 2) their ineffective conversion to the corresponding 
diphosphophosphonate analogue; or 3) their weak affinity for the target polymerases 
and/or lack of incorporation into viral RNA. If uptake into the cell would be the 
bottleneck, converting the phosphonates to an appropriate prodrug form could be 
considered. 
Conclusion 
In conclusion, this study described the synthesis, structural analysis and antiviral 
activity of a small series of 2’-deoxyuridine analogues that combine different aromatic 
substituents at position 5 of the base and a 5’-methylene phosphonate modification at 
the sugar moiety. All compounds were synthesized via an 8-step procedure, featuring a 
Wittig reaction and Suzuki-Miyaura coupling. An unexpected anomerisation during the 
last step of the synthesis allowed us to investigate the β- as well as the α-anomers of the 
corresponding phosphonates. None of these analogues exhibited significant antiviral 
activity 
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 Experimental section 
Synthesis. General. All reagents were from standard commercial sources and of 
analytical grade. Precoated Merck silica gel F254 plates were purchased for TLC, spots 
were examined under ultraviolet light at 254 nm and further visualized by sulfuric acid-
anisaldehyde spray. Column chromatography was performed on silica gel (63-200 μm, 
60 Å, Biosolve, Valkenswaard, The Netherlands). With the exception of the 
13
C NMR 
spectrum of compound 1a, which was recorded on a 500 MHz Bruker DRX apparatus, 
all NMR spectra were determined using a Varian Mercury 300 MHz spectrometer. 
Chemical shifts are given in ppm (δ) relative to the residual solvent signals, which in the 
case of DMSO-d6 were 2.54 ppm for 
1
H and 40.5 ppm for 
13
C. Structural assignment 
was confirmed with COSY and DEPT. All signals assigned to hydroxyl groups were 
exchangeable with D2O. Exact mass measurements were performed on a Waters LCT 
Premier XETM Time of flight (TOF) mass spectrometer equipped with a standard 
electrospray ionization (ESI) and modular LockSpray TM interface. Samples were 
infused in a CH3CN/water (1:1) mixture at 10 μL/min. 
1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-D-hex-5-
enofuranosyl]-uracil (7). 2’-Iodoxybenzoic acid (550 mg, 1.97 mmol) was added to a 
solution of 6 (449 mg, 1.31 mmol) in CH3CN (12 mL) and the resulted suspension was 
stirred at 80 °C for 6 h. After cooling in an ice bath (15 min), the solid was removed by 
filtration and washed with cold CH3CN. The solvent was evaporated and the residue 
was co-distilled with toluene. The residue was dissolved in anhydrous DMSO (3.4 mL) 
and freshly prepared [(diethoxyphosphinyl)methyl]triphenylphosphorane in DMSO (3.4 
mL) was added. After 20 h, the mixture was poured into water and extracted with 
CH2Cl2. The combined organic layers were dried over MgSO4, filtered and concentrated 
in vacuo. The residue was lyophilized to remove the remaining DMSO and purified on a 
silica gel column (CH2Cl2/MeOH 98:2) yielding 257 mg (41%) of 7 as a colourless 
solid. 
1
H NMR (300 MHz, DMSO-d6): δ 0.070 (6H, s, TBDMS), 0.87 (9H, s, TBDMS), 
1.23 (6H, app dt, J= 1.5 Hz, J= 6.9 Hz, 2 x OCH2CH3), 2.13-2.22 (1H, m, H-2’a), 2.34-
2.43 (1H, m, H-2’b), 3.92-4.03 (4H, m, 2 x OCH2CH3), 4.20-4.25 (1H, m, H-4’), 4.38-
4.45 (1H, m, H-3’), 5.64 (1H, d, J= 7.8 Hz, CH=CH), 5.96-6.09 (1H, m, H-6’), 6.16 
(1H, dd, J= 6.0 Hz, J= 7.5 Hz, H-1’), 6.60-6.75 (1H, m, H-5’), 7.68 (1H, d, J= 8.4 Hz, 
CH=CH), 11.34 (1H, s, 3-NH). 
31
P NMR (DMSO-d6): δ 17.21. 
13
C NMR (75 MHz, 
DMSO-d6): δ -5.02, -4.87 (TBDMS), 16.10, 16.18 (OCH2CH3), 17.60 (TBDMS), 25.57 
(TBDMS), 61.21, 61.31 (OCH2CH3), 74.36 (C-3’), 84.27 (C-1’), 85.27 (C-4’, d, J= 23 
Hz), 102.07 (C-5), 119.70 (C-6’, d, J= 182 Hz), 141.38 (C-6), 147.81 (C-5’, d, J= 5 
Hz), 150.29 (C-2), 162.98 (C-4). Exact mass (ESI-MS) for C20H36N2O7PSi [M+H]
+
 
found, 475.2035; calcd, 475.2024. 
1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-D-
hexofuranosyl]-uracil (8). To a solution of compound 7 (257 mg, 0.54 mmol) in 
MeOH (8 mL) was added 10% Pd/C. The reaction mixture was stirred under hydrogen 
atmosphere overnight. The catalyst was removed by filtration through Celite and the 
filtrate was evaporated to yield pure compound 8 (250 mg, 97%) as a colourless solid. 
1
H NMR (300 MHz, DMSO-d6): δ 0.084 (6H, app d, J= 2.4 Hz, TBDMS), 0.87 (9H, s, 
TBDMS), 1.22 (6H, t, J= 6.9 Hz, 2 x OCH2CH3), 1.65-1.86 (4H, m, H-5’a, H-5’b, H-
6’a and H-6’b), 2.00-2.15 (1H, m, H-2’a), 2.22-2.31 (1H, m, H-2’b), 3.68-3.72 (1H, m, 
H-3’), 3.92-4.04 (4H, m, 2 x OCH2CH3), 4.23-4.29 (1H, m, H-4’), 5.62 (1H, d, J= 8.1 
Hz, CH=CH), 6.10 (1H, t, J= 6.6 Hz, H-1’), 7.59 (1H, d, J= 8.4 Hz, CH=CH), 11.32 
(1H, s, 3-NH).
31
P NMR (DMSO-d6): δ 31.72.
13
C NMR (75 MHz, DMSO-d6): δ -5.04, -
4.99 and -4.73 (TBDMS), 16.21 and 16.28 (OCH2CH3)2, 17.58 (TBDMS), 20.97 (C-6’, 
d, J= 139 Hz), , 25.69 (C5’, d, J= 12Hz), 60.90, 60.97 (OCH2CH3)2, 73.84 (C-3’), 84.95 
(C-4’, d, J= 16 Hz), 83.61 (C-1’), 102.10 (C-5), 141.03 (C-6), 150.40 (C-2), 163.11 (C-
4). Exact mass (ESI-MS) for C20H38N2O7PSi [M+H]
+
 found, 477.2119; calcd, 477.2180. 
1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-D-
hexofuranosyl]-5-bromouracil (9). To a solution of compound 8 (950 mg, 1.99 mmol) 
in DMF (15 mL) was added N-bromosuccinimide (NBS, 390 mg, 2.19 mmol) under N2. 
The reaction mixture was stirred at room temperature for 16 hours. DMF was removed 
in vacuo and the residue was purified by column chromatography (CH2Cl2/MeOH 97:3) 
to afford 9 (538 mg, 49%) as a white foam.
 1
H NMR (300 MHz, CDCl3): δ 0.082 (6H, 
app d, J= 1.8 Hz, TBDMS), 0.89 (9H, s, TBDMS), 1.34 (6H, t, J= 6.9 Hz, 2 x 
OCH2CH3), 1.82-2.02 (4H, m, H-5’a, H-5’b, H-6’a and H-6’b), 2.09-2.16 (1H, m, H-
2’a), 2.29-2.32 (1H, m, H-2’b), 3.81-3.84 (1H, m, H-4’), 4.07-4.19 (5H, m, 2 x 
OCH2CH3, H-3’), 6.13 (1H, t, J= 6.3 Hz, H-1’), 7.65 (1H, s, H-6), 9.83 (1H, s, 3-
NH).
31
P NMR (CDCl3): δ 30.90. 
13
C NMR (75 MHz, CDCl3): δ -4.83, -4.56 (TBDMS), 
16.46, 16.54 (OCH2CH3)2, 17.89 (TBDMS), 22.33 (C-6’, d, J= 143 Hz), 25.68 
(TBDMS), 26.56 (C-5’, d, J= 4.1 Hz), 40.85 (C-2’), 61.80, 61.83 (OCH2CH3)2, 74.50 
(C-3’), 85.57 (C-1’), 86.53 (C-4’, d, J= 17.0 Hz), 97.10 (C-5), 139.01 (C-6), 149.47 (C-
2), 159.03 (C-4). Exact mass (ESI-MS) for C20H37BrN2O7PSi [M+H]
+
 found, 555.1323; 
calcd, 555.1286. 
General procedure for the synthesis of 5-modified nucleoside phosphonates via 
Suzuki-Miyaura coupling . A mixture of compound 9 (1 equiv.), aryl boronic acid (2 
equiv.), Pd(PPh3)4 (0.1 equiv.) and Na2CO3 (3.3 equiv.) in DMF and degassed H2O was 
heated (± 130 °C, oil bath) under argon for 6 h or until TLC indicated consumption of 
all starting material. The mixture was then concentrated and co-distilled with toluene. 
The residue was purified by column chromatography (CH2Cl2/MeOH 94:6-98:2) 
affording the 5-modified analogues in moderate yield. 
1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-D-
hexofuranosyl]-5-phenyluracil (10). Reaction of compound 9 (153 mg, 0.27 mmol) 
with phenylboronic acid (68 mg, 0.55 mmol), Pd(PPh3)4 (32 mg, 0.027 mmol) and 
Na2CO3 (96 mg, 0.91 mmol) in DMF (6.5 mL) and degassed H2O (0.8 mL) was 
performed as described in the general procedure to yield compound 10 as a colourless 
solid (120 mg, 79%). 
1
H NMR (300 MHz, CDCl3): δ 0.084 (6H, s, TBDMS), 0.90 (9H, 
s, TBDMS), 1.25-1.32 (6H, m, 2 x OCH2CH3), 1.73-2.04 (4H, m, H-5’a, H-5’b, H-6’a 
and H-6’b), 2.11-2.20 (1H, m, H-2’a), 2.31-2.39 (1H, m, H-2’b), 3.83-3.86 (1H, m, H-
4’), 4.00-4.11 (5H, m, 2 x OCH2CH3 and H-3’), 6.23 (1H, app t, J= 6.6 Hz, H-1’), 7.33-
7.71 (6H, m, Ph and H-6). 
31
P NMR (CDCl3): δ 30.69. 
13
C NMR (75 MHz, CDCl3): δ -
4.73 and -4.46 (TBDMS), 16.48, 16.56 (OCH2CH3)2, 18.00 (TBDMS), 22.39 (C-6’, d, 
J= 143 Hz), 25.80 (TBDMS), 26.60 (C-5’, d, J= 4.4 Hz), 40.67 (C-2’), 61.89 and 61.92 
((OCH2CH3)2, d, J= 6.5Hz , 74.75 (C-3’), 85.30 (C-1’), 86.42 (C-4’, d, J= 17.0 Hz), 
115.67 (C-5), 128.07-133.10 (Ph), 136.95 (C-6), 150.02 (C-2), 162.39 (C-4). Exact 
mass (ESI-MS) for C26H42N2O7PSi [M+H]
+
 found, 553.2485; calcd, 553.2493. 
1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-D-
hexofuranosyl]-5-(naphthalen-1-yl)uracil (11). Reaction of compound 9 (122 mg, 
0.22 mmol) with naphthalene-1-boronic acid (75 mg, 0.44 mmol), Pd(PPh3)4 (25 mg, 
0.022 mmol) and Na2CO3 (77 mg, 0.72 mmol) in DMF (5 mL) and degassed H2O (0.7 
mL) was performed as described in the general procedure to afford compound 11 as a 
colourless solid (120 mg, 91%). 
1
H NMR (300 MHz, CDCl3): δ 0.056 (6H, s, TBDMS), 
0.87 (9H, s, TBDMS), 1.15-1.24 (6H, m, 2 x OCH2CH3), 1.77-2.03 (4H, m, H-5’a, H-
5’b, H-6’a and H-6’b), 2.12-2.18 (1H, m, H-2’a), 2.26-2.31 (1H, m, H-2’b), 3.82 (1H, 
app s, H-4’), 3.95-4.13 (5H, m, 2 x OCH2CH3 and H-3’), 6.24 (1H, app t, J= 6.6 Hz, H-
1’), 7.42-7.82 (7H, m, naphthalene), 7.98 (1H, s, H-6), 8.43 (1H, s, 3-NH). 31P NMR 
(CDCl3): δ 30.95. 
13
C NMR (75 MHz, CDCl3): δ -4.87 and -4.62 (TBDMS), 16.2, 16.3 
(OCH2CH3), 17.85 (TBDMS), 22.26 (C-6’, d, J= 143 Hz), 25.65 (TBDMS), 23.46 (C-
5’), 40.50 (C-2’), 61.63, 61.71 (OCH2CH3), 74.63 (C-3’), 85.26 (C-1’), 86.29 (C-4’, d, 
J= 17.0 Hz), 115.45 (C-5), 125.89-133.22 (naphthalene), 136.91 (C-6), 149.88 (C-2), 
162.26 (C-4). Exact mass (ESI-MS) for C30H44FN2O7PSi [M+H]
+
 found, 603.2675; 
calcd, 603.2650. 
1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-D-
hexofuranosyl]-5-(4-fluorophenyl)uracil (12). Reaction of compound 9 (163 mg, 0.29 
mmol) with 4-fluorophenylboronic acid (82 mg, 0.59 mmol), Pd(PPh3)4 (34 mg, 0.029 
mmol) and Na2CO3 (102 mg, 0.97 mmol) in DMF (7 mL) and degassed H2O (0.9 mL) 
was performed as described in the general procedure to yield compound 12 as a 
colourless solid (141 mg, 84%). 
1
H NMR (300 MHz, CDCl3): δ 0.010 (6H, s, TBDMS), 
0.80-0.84 (9H, m, TBDMS), 1.21 (6H, app q, J= 7.2 Hz, 2 x OCH2CH3), 1.68-1.94 (4H, 
m, H-5’a, H-5’b, H-6’a and H-6’b), 2.02-2.11 (1H, m, H-2’a), 2.23-2.31 (1H, m, H-
2’b), 3.74-3.78 (1H, m, H-4’), 3.93-4.02 (5H, m, 2 x OCH2CH3 and H-3’), 6.14 (1H, 
app t, J= 6.9 Hz, H-1’), 6.99-7.04 (2H, m, subs Ph), 7.34-7.42 (3H, m, subs Ph and H-
6), 8.25 (1H, s, 3-NH). 
31
P NMR (CDCl3): δ 30.74. 
13
C NMR (75 MHz, CDCl3): δ -
4.59,  -4.33 (TBDMS), 16.64, 16.72 (OCH2CH3), 18.14 (TBDMS), 22.65 (C-6’, d, J= 
143 Hz), 25.91 (TBDMS), 26.89 (C-5’, d, J= 5.0 Hz), 40.95 (C-2’), 61.89, 62.01 
(OCH2CH3), 74.89 (C-3’), 85.60 (C-1’), 86.55 (C-4’, d, J= 17 Hz), 115.00 (C-5), 
128.42-132.40 (naphthalene), 136.74 (C-6), 149.55 (C-2), 161.72 (C-4). Exact mass 
(ESI-MS) for C26H41FN2O7PSi [M+H]
+
 found, 571.2430; calcd, 571.2399. 
1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-D-
hexofuranosyl]-5-(thiophen-2-yl)uracil (13). Reaction of compound 9 (155 mg, 0.28 
mmol) with thiophene-2-boronic acid (71 mg, 0.56 mmol), Pd(PPh3)4 (32 mg, 0.028 
mmol) and Na2CO3 (98 mg, 0.92 mmol) in DMF (6.7 mL) and degassed H2O (0.8 mL) 
was performed as described in the general procedure to yield compound 13 as a 
colourless solid (117 mg, 75%). 
1
H NMR (300 MHz, CDCl3): δ 0.090 (6H, s, TBDMS), 
0.90 (9H, s, TBDMS), 1.26-1.37 (6H, m, 2 x OCH2CH3), 1.83-2.08 (4H, m, H-5’a, H-
5’b, H-6’a and H-6’b), 2.14-2.23 (1H, m, H-2’a), 2.32-2.40 (1H, m, H-2’b), 3.85-3.90 
(1H, m, H-4’), 4.06-4.18 (5H, m, 2 x OCH2CH3 and H-3’), 6.23 (1H, app t, J= 6.3 Hz, 
H-1’), 7.01-7.04 (1H, m, thiophene), 7.25-7.29 (1H, m, thiophene), 7.39-7.44 (1H, m, 
thiophene), 7.69 (1H, s, H-6), 9.97 (1H, s, 3-NH). 
31
P NMR (CDCl3): δ 30.80. 
13
C NMR 
(75 MHz, CDCl3): δ -4.77 and -4.50 (TBDMS), 16.48, 16.56 (OCH2CH3), 17.95 
(TBDMS), 22.36 (C-6’, d, J= 143 Hz), 25.74 (TBDMS), 26.69 (C-5’, d, J= 4.7 Hz), 
40.91 (C-2’), 61.79, 61.86 (OCH2CH3), 74.64 (C-3’), 85.62 (C-1’), 86.55 (C-4’, d, J= 
16.8 Hz), 110.20 (C-5), 124.42, 125.37, 127.10 and 133.63 (thiophene), 134.32 (C-6), 
149.39 (C-2), 161.27 (C-4). Exact mass (ESI-MS) for C24H40N2O7PSSi [M+H]
+
 found, 
559.2058; calcd, 559.2058. 
1-[2,5,6-Trideoxy-6-(diethoxyphosphinyl)-β-D-hexofuranosyl]-5-phenyluracil (14). 
Compound 10 (115 mg, 0.21 mmol) was dissolved in THF (1.3 mL). A solution of 1 M 
TBAF in THF (0.46 mmol, 0.46 mL) was added. After stirring for 1 h at room 
temperature, the reaction was completed. The solvent was evaporated and the dry 
residue was purified by column chromatography (CH2Cl2/MeOH 96:4) to give pure 
compound 14 (65 mg, colourless solid) in 71% yield. 
1
H NMR (300 MHz, DMSO-d6): δ 
1.18 (6H, dt, J= 1.8 Hz, J= 6.9 Hz, 2 x OCH2CH3), 1.75-1.83 (4H, m, H-5’a, H-5’b, H-
6’a and H-6’b), 2.06-2.14 (1H, m, H-2’a), 2.36-2.51 (1H, m, H-2’b), 3.71-3.72 (1H, m, 
H-4’), 3.89-3.99 (4H, m, 2 x OCH2CH3), 4.06-4.12 (1H, m, H-3’), 5.29 (1H, d, J= 4.5 
Hz, 3’-OH), 6.17 (1H, t, J= 6.9 Hz, H-1’), 7.29-7.40 (3H, m, Ph), 7.51-7.54 (2H, m, 
Ph), 7.63 (1H, s, H-6). 
31
P NMR (DMSO-d6): δ 31.80. 
13
C NMR (75 MHz, DMSO-d6): 
δ 16.13, 16.20 (OCH2CH3), 21.20 (C-6’, d, J= 139 Hz), 26.01 (C-5’, d, J= 4.7 Hz), 
60.82, 60.85 ((OCH2CH3)2, 2d, J= 6.3 Hz)), 72.80 (C-3’), 84.46 (C-1’), 85.74 (C-4’, d, 
J= 17.0 Hz), 113.07 (C-5), 114.76, 115.04, 129.29, 129.34, 130.23 and 130.34 (Ph), 
137.87 (C-6), 149.89 (C-6), 162.05 (C-4). Exact mass (ESI-MS) for C20H28N2O7P 
[M+H]
+
 found: 439.1639, calcd: 439.1686. 
1-[2,5,6-Trideoxy-6-(diethoxyphosphinyl)-β-D-hexofuranosyl]-5-(naphthalen-1-yl)-
uracil (15). Compound 11 (120 mg, 0.20 mmol) was deprotected using the same 
procedure as described for the synthesis of compound 14. Compound 15 was obtained 
as a colourless solid in a 65% yield (63 mg). 
1
H NMR (300 MHz, CDCl3): δ 1.17-1.25 
(6H, m, 2 x OCH2CH3), 1.77-2.02 (4H, m, H-5’a, H-5’b, H-6’a and H-6’b), 2.12-2.21 
(1H, m, H-2’a), 2.40-2.53 (1H, m, H-2’b), 3.91-4.07 (5H, m, 2 x OCH2CH3 and H-4’), 
4.16-4.20 (1H, m, H-3’), 5.28 (1H, s, 3’-OH), 6.26 (1H, t, J= 6.6 Hz, H-1’), 7.40-7.46 
(2H, m, naphthalene), 7.53-7.58 (2H, m, naphthalene), 7.75-7.84 (3H, m, naphthalene), 
7.96 (1H, s, H-6). 
31
P NMR (CDCl3): δ 31.46. 
13
C NMR (75 MHz, CDCl3): δ 16.41, 
16.46 ((OCH2CH3)2, d, J= 5.9 Hz), 22.01 (C-6’, d, J= 141 Hz), 26.66 (C-5’), 40.06 (C-
2’), 61.99, 62.06 (OCH2CH3)2, 73.85 (C-3’), 85.43 (C-1’), 86.25 (C-4’, d, J= 16.2 Hz), 
115.60 (C-5), 126.03, 126.31, 126.36, 127.25, 127.62, 128.09, 128.30, 130.00, 132.88 
and 133.34 (naphthalene), 137.17 (C-6), 150.29 (C-6), 162.61 (C-4). Exact mass (ESI-
MS) for C24H30N2O7P [M+H]
+
 found: 489.1814, calcd: 489.1785. 
1-[2,5,6-Trideoxy-6-(diethoxyphosphinyl)-β-D-hexofuranosyl]-5-(4-fluorophenyl)-
uracil (16). Compound 12 (135 mg, 0.24 mmol) was deprotected using the same 
procedure as described for the synthesis of compound 14. Compound 16 was obtained 
as a colourless solid in a 32% yield (35 mg). 
1
H NMR (300 MHz, DMSO-d6): δ 1.18 
(6H, dt, J= 2.4 Hz, J= 6.9 Hz, 2 x OCH2CH3), 1.70-1.82 (4H, m, H-5’a, H-5’b, H-6’a 
and H-6’b), 2.05-2.13 (1H, m, H-2’a), 2.37-2.44 (1H, m, H-2’b), 3.70-3.71 (1H, m, H-
4’), 3.89-3.99 (4H, m, 2 x OCH2CH3), 4.06-4.09 (1H, m, H-3’), 5.28 (1H, d, J= 4.5 Hz, 
3’-OH), 6.16 (1H, t, J= 7.2 Hz, H-1’), 7.17-7.23 (2H, m, subs Ph), 7.55-7.60 (2H, m, 
subs Ph), 7.64 (1H, s, H-6), 11.53 (1H, s, 3-NH). 
31
P NMR (DMSO-d6): δ 31.80. 
13
C 
NMR (75 MHz, DMSO-d6): δ 16.2, 16.3 (OCH2CH3), 21.22 (C-6’, d, J= 139 Hz), 26.11 
(C-5’, d, J= 5 Hz), 60.99, 61.95 ((OCH2CH3)2, 2d, J= 6.1 Hz), 72.80 (C-3’), 84.61 (C-
1’), 85.86 (C-4’, d, J= 16.7 Hz), 113.07 (C-5), 114.76, 115.04, 129.29, 129.34, 130.23 
and 130.34 (subs Ph), 137.87 (C-6), 149.89 (C-6), 162.05 (C-4). Exact mass (ESI-MS) 
for C20H27FN2O7P [M+H]
+
 found, 457.1547; calcd, 457.1534. 
1-[2,5,6-Trideoxy-6-(diethoxyphosphinyl)-β-D-hexofuranosyl]-5-(thiophen-2-yl)-
uracil (17). Compound 13 (117 mg, 0.21 mmol) was deprotected using the same 
procedure as described for the synthesis of compound 14. Compound 17 was obtained 
as a colourless solid in a 63% yield (59 mg). 
1
H NMR (300 MHz, CDCl3): δ 1.31 (6H, 
app dt, J= 2.1 Hz, J= 6.9 Hz, 2 x OCH2CH3), 1.86-2.08 (4H, m, H-5’a, H-5’b, H-6’a 
and H-6’b), 2.18-2.27 (1H, m, H-2’a), 2.46-2.54 (1H, m, H-2’b), 3.97-3.98 (1H, m, H-
4’), 4.04-4.15 (4H, m, 2 x OCH2CH3), 4.19-4.26 (1H, m, H-3’), 5.30 (1H, s, 3’-OH), 
6.25 (1H, app t, J= 6.6 Hz, H-1’), 6.97-7.00 (1H, m, thiophene), 7.24 (1H, d, J= 4.8 Hz, 
thiophene), 7.36 (1H, d, J= 3.0 Hz, thiophene), 7.69 (1H, s, H-6). 
31
P NMR (CDCl3): δ 
31.48. 
13
C NMR (75 MHz, CDCl3): δ 16.50, 16.58 (OCH2CH3)2, 22.05 (C-6’, d, J= 142 
Hz), 26.67 (C-5’), 40.27 (C-2’), 62.07, 62.17 (OCH2CH3)2, 73.80 (C-3’), 85.72 (C-1’), 
86.40 (C-4’, d, J= 15.9 Hz), 110.19 (C-5), 124.35, 125.45, 127.08 and 133.64 
(thiophene), 134.55 (C-6), 149.77 (C-2), 161.52 (C-4). Exact mass (ESI-MS) for 
C18H26N2O7PS [M+H]
+
 found, 445.1210; calcd, 445.1193. 
General procedure for the deprotection of 5-modified nucleoside phosphonates  
The phosphonic ester (1 equiv.) was dissolved in CH2Cl2 under argon. TMSBr (2 
equiv.) was added and the resulting solution was stirred overnight. The solvent was 
evaporated and the residue dissolved in a mixture of EtOAc/Et2O (1:1) and water. The 
organic phase was washed with water and the water layers were combined and 
lyophilized. Purification of the crude using RP-HPLC (Phenomenex Luna C-18, 
H2O/0.1% HCOOH in CH3CN, 90:10 → 0:100 in 23 min, flow 17.5 mL/min) afforded 
2 series of compounds: the α- (retention time ≥ 12 min) and β-isomer (retention time ≈ 
10-11 min) of each phosphonate. 
1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)-β-D-hexofuranosyl]-5-phenyluracil (1a) 
and 1-[2,5,6-trideoxy-6-(dihydroxyphosphinyl)-α-D-hexofuranosyl]-5-phenyluracil 
(1b) Reaction of compound 14 (27 mg, 0.061 mmol) with TMSBr (16 μL, 0.12 mmol) 
in CH2Cl2 (0.9 mL) as described in the general procedure affording the β- (1a, 0.9 mg, 
4%) and α-isomer (1b, 3.2 mg, 14%) as white powders. Compound 1a: 1H NMR (300 
MHz, DMSO-d6): δ 1.52-1.55 (2H, m, H-6’a and H-6’b), 1.79-1.91 (2H, m, H-5’a and 
H-5’b), 2.07-2.11 (1H, m, H-2’a), 2.29-2.38 (1H, m, H-2’b), 3.73 (1H, app s, H-4’), 
4.06 (1H, app s, H-3’), 6.14 (1H, t, J= 6.6 Hz, H-1’), 7.27-7.40 (3H, m, Ph), 7.51-7.54 
(2H, m, Ph), 7.63 (1H, s, H-6). 
31
P NMR (DMSO-d6): δ 24.44. 
13
C NMR (125 MHz, 
DMSO-d6): δ 24.56 (C-6’, d, J= 146 Hz), 27.22 (C-5’), 38.75 (C-2’), 72.76 (C-3’), 
84.30 (C-1’), 86.57 (C-4’, d, J= 19.3 Hz), 113.89 (C-5), 127.31 (para), 128.10 (ortho), 
128.21 (meta), 132.91 (ipsa) (Ph), 137.58 (C-6), 149.86 (C-2), 162.08 (C-4). Exact mass 
(ESI-MS) for C16H18N2O7P [M-H]
-
 found, 381.0836; calcd, 381.0857; Compound 1b: 
1
H NMR (300 MHz, DMSO-d6): δ 1.49-1.57 (4H, m, H-5’a, H-5’b, H-6’a and H-6’b), 
1.98 (1H, app d, J= 14.1 Hz, H-2’a), 2.57-2.65 (1H, m, H-2’b), 4.11 (1H, app s, H-4’), 
4.23 (H, app s, H-3’), 6.14 (1H, app d, J= 6.6 Hz, H-1’), 7.27-7.38 (3H, m, Ph), 7.51-
7.54 (2H, m, Ph), 8.16 (1H, s, H-6). 
31
P NMR (DMSO-d6): δ 23.62. Exact mass (ESI-
MS) for C16H18N2O7P [M-H]
-
 found, 381.0851; calcd, 381.0857. 
1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)-β-D-hexofuranosyl]-5-(naphtalen-1-
yl)uracil (2a) and 1-[2,5,6-trideoxy-6-(dihydroxyphosphinyl)-α-D-hexofuranosyl]-5-
(naphthalen-1-yl)uracil (2b). Reaction of compound 15 (63 mg, 0.13 mmol) with 
TMSBr (34 μL, 0.26 mmol) in CH2Cl2 (1.9 mL) as described in the general procedure 
affording the β- (2a, 7.05 mg, 13%) and α-isomer (2b, 8.77 mg, 16%) as white powders. 
Compound 2a: 
1
H NMR (300 MHz, DMSO-d6): δ 1.47 (2H, app br s, H-6’a and H-6’b), 
1.80 (2H, app br s, H-5’a and H-5’b), 2.13 (1H, app br s, H-2’a), 2.27 (1H, app br s, H-
2’b), 3.79 (1H, app s, H-4’), 4.09-4.14 (1H, m, H-3’), 6.14 (1H, app s, H-1’), 7.49-8.27 
(8H, m, naphthalene and H-6). 
31
P NMR (DMSO-d6): δ 20.97. Exact mass (ESI-MS) for 
C20H20N2O7P [M-H]
-
 found: 431.1041, calcd: 431.1014; Compound 2b: 
1
H NMR (300 
MHz, DMSO-d6): δ 1.59 (4H, app br s, H-5’a, H-5’b, H-6’a and H-6’b), 1.99-2.06 (1H, 
m, H-2’a), 2.52-2.70 (1H, m, H-2’b), 4.13 (1H, app s, H-4’), 4.27 (1H, app s, H-3’), 
6.18 (1H, app d, J= 5.7 Hz, H-1’), 7.46-7.52 (2H, m, naphthalene), 7.66 (2H, d, J= 8.4 
Hz, naphthalene), 7.88-7.91 (3H, m, naphthalene), 8.12 (1H, s, naphthalene), 8.31 (1H, 
s, H-6). 
31
P NMR (DMSO-d6): δ 24.28. 
13
C NMR (75 MHz, DMSO-d6): δ 72.61 (C-3’), 
85.41 (C-1’), 89.23 (C-4’), 112.48 (C-5), 125.95-132.84 (naphthalene), 139.65 (C-6), 
150.02 (C-2), 162.35 (C-4). Exact mass (ESI-MS) for C20H20N2O7P [M-H]
-
 found: 
431.1009, calcd: 431.1014. 
1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)-β-D-hexofuranosyl]-5-(4-
fluorophenyl)uracil (3a) and 1-[2,5,6-trideoxy-6-(dihydroxyphosphinyl)-α-D-
hexofuranosyl]-5-(4-fluorophenyl)uracil (3b). Reaction of compound 16 (36 mg, 
0.078 mmol) with TMSBr (21 μL, 0.16 mmol) in CH2Cl2 (1.0 mL) as described in the 
general affording the β- (3a, 1.69 mg, 6%) and α-isomer (3b, 3.19 mg, 12%) as white 
powders. Compound 3a: 
1
H NMR (300 MHz, DMSO-d6): δ 1.43 (2H, app br s, H-6’a 
and H-6’b), 1.76 (2H, app br s, H-5’a and H-5’b), 2.09 (1H, app br s, H-2’a), 2.28 (1H, 
app br s, H-2’b), H-4’ under H2O peak, 4.08 (1H, app s, H-3’), 6.09 (1H, app s, H-1’), 
7.21-7.62 (5H, m, subs Ph and H-6). 
31
P NMR (DMSO-d6): δ 20.60. Exact mass (ESI-
MS) for C16H17FN2O7P [M-H]
-
 found: 399.0762, calcd: 399.0763; Compound 3b: 
1
H 
NMR (300 MHz, DMSO-d6): δ 1.44-1.58 (4H, m, H-5’a, H-5’b, H-6’a and H-6’b), 1.99 
(1H, d, J= 13.5 Hz, H-2’a), 2.52-2.65 (1H, m, H-2’b), 4.11 (1H, app s, H-4’), 4.20-4.25 
(1H, m, H-3’), 6.12 (1H, app d, J= 6.9 Hz, H-1’), 7.19 (2H, app t, J= 8.7 Hz, subs Ph), 
7.54-7.59 (2H, m, subs Ph), 8.15 (1H, s, H-6), 8.33 (1H, s, subs Ph). 
31
P NMR (DMSO-
d6): δ 22.19.
13
C NMR (75 MHz, DMSO-d6): δ 72.22 (C-3’), 85.16 (C-1’), 111.49 (C-5), 
114.67, 114.96, 129.57, 129.67 (Ph), 139.00 (C-6), 149.84 (C-2), 162.04 (C-4). Exact 
mass (ESI-MS) for C16H17FN2O7P [M-H]
-
 found: 399.0743, calcd: 399.0763. 
1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)-β-D-hexofuranosyl]-5-(thiophen-2-
yl)uracil (4a) and 1-[2,5,6-trideoxy-6-(dihydroxyphosphinyl)-α-D-hexofuranosyl]-5-
(thiophen-2-yl)uracil (4b). Reaction of compound 17 (59 mg, 0.13 mmol) with TMSBr 
(35 μL, 0.27 mmol) in CH2Cl2 (2.0 mL) as described in the general procedure affording 
the β- (4a, 5.2 mg, 10%) and α-isomer (4b, 9.6 mg, 19%) as white powders. Compound 
4a: 
1
H NMR (300 MHz, DMSO-d6): δ 1.50 (2H, app br s, H-6’a and H-6’b), 1.80 (2H, 
app br s, H-5’a and H-5’b), 2.04-2.12 (1H, m, H-2’a), 2.27-2.31 (1H, m, H-2’b), 3.80 
(1H, app br s, H-4’), 4.09 (1H, app br s, H-3’), 6.10 (1H, d, J= 6.6 Hz, H-1’), 7.06 (1H, 
t, J= 4.8 Hz, thiophene), 7.45 (2H, app dd, J= 4.8 Hz, J= 14.4 Hz, thiophene), 7.89 (1H, 
s, H-6). 
31
P NMR (DMSO-d6): δ 23.13. 
13
C NMR (75 MHz, CDCl3): δ (C-6’, C-5’ and 
C-2’ not visible), 73.42 (C-3’), 85.35 (C-1’), 109.21 (C-5), 123.93, 126.37, 
127.43,134.26 (thiophene), 135.74 (C-6), 149.97 (C-2), 161.94 (C-4). Exact mass (ESI-
MS) for C14H16N2O7PS [M-H]
-
 found:387.0377, calcd: 387.0421; Compound 4b: 
1
H 
NMR (300 MHz, DMSO-d6): δ 1.40-1.72 (4H, m, H-5’a, H-5’b, H-6’a and H-6’b), 2.02 
(1H, app d, J= 14.4 Hz, H-2’a), 2.59-2.68 (1H, m, H-2’b), 4.13 (1H, app d, J= 4.8 Hz, 
H-3’), 4.27 (4H, app s, H-4’), 6.16 (1H, app d, J= 5.7 Hz, H-1’), 7.04-7.07 (1H, dd, J= 
3.6 Hz, J= 4.8 Hz, thiophene), 7.37-7.38 (1H, m, thiophene), 7.44-7.45 (1H, m, 
thiophene), 8.46 (1H, s, H-6). 
31
P NMR (DMSO-d6): δ 25.63. 
13
C NMR (75 MHz, 
DMSO-d6): δ 24.29 (C-6’, d, J= 135 Hz), 27.01 (C-5’), (C-2’ under DMSO peak), 72.59 
(C-3’), 85.51 (C-1’), 88.91 (C-4’, d, J= 15.7 Hz), 107.71 (C-5), 122.58, 125.47, 
126.54,134.28 (thiophene), 136.98 (C-6), 149.53 (C-2), 161.87 (C-4). Exact mass (ESI-
MS) for C14H16N2O7PS [M-H]
-
 found: 387.0416, calcd: 387.0421.  
1-[2,5,6-Trideoxy-6-(diethoxyphosphinyl)-β-D-hexofuranosyl]-uracil (18). 
Compound 8 (309 mg, 0.65 mmol) was dissolved in 4.1 mL THF and a TBAF solution 
in THF (1M, 1.44 mL, 1.44 mmol) was added at rt. After stirring for 3 h the reaction 
mixture was evaporated in vacuo and poured on a silica column (CH2Cl2/MeOH 92:8) 
to give compound 18 (162 mg, 69%) as a colourless solid. 
1
H NMR (300 MHz, DMSO-
d6): δ 1.23 (6H, t, J= 6.9 Hz, 2 x OCH2CH3), 1.68-1.82 (4H, m, H-5’a, H-5’b, H-6’a and 
H-6’b), 2.04-2.24 (2H, m, H-2’a and H-2”), 3.66-3.68 (1H, m, H-4’), 3.92-4.08 (5H, m, 
2 x OCH2CH3 and H-3’), 5.30 (1H, d, J= 4.5 Hz, 3’-OH), 5.63 (1H, d, J= 8.7 Hz, 
CH=CH), 6.10 (1H, t, J= 6.6 Hz, H-1’), 7.58 (1H, d, J= 7.8 Hz, CH=CH), 11.31 (1H, s, 
3-NH). 
31
P NMR (DMSO-d6): δ 31.89. 
13
C NMR (75 MHz, DMSO-d6): δ 16.26,16.33 
(OCH2CH3), 21.07 (C-6’, d, J= 139 Hz), 25.95 (C-5’, d, J= 4.1 Hz), 60.93, 60.96 
(OCH2CH3, d, J= 6.3 Hz ), 72.52 (C-3’), 83.65 (C-1’), 85.43 (C-4’, J= 16.8 Hz), 102.08 
(C-5), 140.79 (C-6), 150.45 (C-2), 163.10 (C-4). Exact mass (ESI-MS) for 
C14H24N2O7P [M+H]
+
 found, 363.1308; calcd, 363.1316. 
1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)-β-D-hexofuranosyl]-uracil (5a) and 1-
[2,5,6-trideoxy-6-(dihydroxyphosphinyl)-α-D-hexofuranosyl]-uracil (5b). To a 
solution of 18 (40 mg, 0.11 mmol) in CH2Cl2 (1.6 mL) was added TMSBr (29 μL, 0.22 
mmol). After stirring overnight, the volatiles were removed in vacuo. The residue was 
dissolved in water, washed with EtOAc/Et2O (1:1) and lyophilized. A 3:2 mixture of the 
α- and β-isomer (25 mg, 65%) was obtained as a yellow powder. 1H NMR (300 MHz, 
D2O): δ 1.48-1.91 (4.4H, m, H-5’a, H-5’b, H-6’a, H-6’b and minor isomer H-2’a), 2.12-
2.17 (0.6H, major isomer, m, H-2’b), 2.34-2.38 (0.6H, major isomer, m, H-2’a), 2.72-
2.80 (0.4 H, minor isomer, m, H-2’b), 3.94-4.00 (0.4H, minor isomer, m, H-3’), 4.31-
4.37 (1.6H, m, major isomer H-3’ and H-4’), 5.85 (0.6H, major isomer, d, J= 7.8 Hz, 
CH=CH), 5.89 (0.4H, minor isomer, d, J= 8.1 Hz, CH=CH), 6.15 (0.6H, major isomer, 
dd, J= 2.7 Hz, J= 7.5 Hz, H-1’), 6.25 (0.4H, minor isomer, app t, J= 6.9 Hz, H-1’), 7.73 
(0.4H, minor isomer, d, J= 8.4 Hz, CH=CH), 7.93 (0.6H, major isomer, d, J= 8.1 Hz, 
CH=CH). 
31
P NMR (DMSO-d6): δ 23.63. 
13
C NMR (75 MHz, DMSO-d6): δ 25.53 
(major isomer, C-6’, d, J= 134 Hz), 27.24 (minor isomer, C-6’, d, J= 128 Hz), 72.72 
(major isomer, C-3’), 72.86 (minor isomer, C-3’), 83.86 (minor isomer, C-1’), 85.25 
(major isomer, C-1’), 87.17 (minor isomer C-4’, d, J= 15.2 Hz), 89.09,  (major isomer, 
C-4’, d, J= 13.7 Hz), 101.13 (major isomer, C-5), 102.33 (minor isomer, C-5), 140.64 
(minor isomer, C-6), 141.67 (major isomer, C-6), 150.62 (minor isomer, C-2), 150.74 
(major isomer, C-2), 163.29 (minor isomer, C-4), 163.56 (major isomer, C-4). Exact 
mass (ESI-MS) for C10H14N2O7P [M-H]
-
 found, 305.0539; calcd, 305.0544. 
Experimental assay. Antiviral and cytotoxicity assays for compounds 1a-4b. The 
antiviral activity of the new compounds was determined using a cytopathogenicity assay 
against herpes simplex virus type 1 (HSV-1) (KOS strain), herpes simplex virus type 2 
(HSV-2) (G strain), vaccinia virus, vesicular stomatitis virus, HSV-1 TK
–
 KOS ACV
r
 in 
HEL cell cultures. Stock solutions of the test compounds were prepared in DMSO at a 
concentration of 10 mg/mL. Cells, grown to confluency in 96-well plates, were infected 
with 100 CCID50 of virus, one CCID50 being the 50% cell culture infective dose in the 
presence of varying concentrations of the test compounds. Cultures were further 
incubated until complete cytopathogenicity was observed in the infected and untreated 
virus control. The cytotoxicity of the compounds was evaluated in parallel with their 
antiviral activity in uninfected cells and is expressed as the minimum cytotoxic 
concentration (MCC) that causes a microscopically detectable alteration of normal cell 
morphology. The symbol ‘‘>’’ is used to indicate the highest concentration at which the 
compounds were tested and found not to be antivirally active. 
For the anti-HCMV and anti-VZV assays, HEL fibroblasts were infected with 100 PFU 
per well. Compounds were added after a 1 h-incubation period, and the cells were 
further incubated at 37 °C. After 5 (VZV) and 7 days (HCMV) of incubation, plaques 
(VZV) or virus-induced cytopathogenicity (HCMV) was monitored microscopically 
after ethanol fixation and staining with Giemsa solution. The cytotoxicity of the 
compounds was evaluated in parallel with their antiviral activity in uninfected cells and 
is expressed as the minimum cytotoxic concentration that causes a microscopically 
detectable alteration of cell morphology (MCC) and the concentration required to 
reduce cell growth by 50% (CC50). 
Determination of the anti-HIV activity of the compounds was based on virus-induced 
cytopathogenicity of HIV-infected CEM cells, measured at day 4 to 5 post virus 
infection by microscopically estimating virus-induced syncytia formation. Results are 
expressed as the 50% effective concentration (EC50) as reported in Table IV.3. The 
cytostatic activity of the compounds was evaluated in parallel with their antiviral 
activity in uninfected cell cultures and is expressed as the 50%-inhibitory concentration 
for the proliferation of the T-lymphocyte CEM cells (EC50). 
 
Figure 1. 2’-Deoxyuridine and envisaged analogues. 
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Scheme 1. Synthesis of 5-modified 2’-deoxyuridine phosphonate analogues. Reagents 
and conditions: (a) 2’-Iodoxybenzoic acid, CH3CN, 80 °C, 6 h; (ii) 
[(diethoxyphosphinyl)methyl]triphenylphosphorane, DMSO, rt, 20 h, 41% over 2 steps; 
(b) H2, Pd/C, MeOH, rt, overnight, 97%; (c) NBS, DMF, rt, overnight, 49%; (d) R-
B(OH)2, Na2CO3, Pd(PPh3)4, DMF, H2O, reflux, 4 h, 75-91%; (e) 1M TBAF in THF, rt, 
1 h, 32-71%; (f) TMSBr, CH2Cl2, rt, overnight, 4-19%. 
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Scheme 2. Synthesis of non-modified 2’-deoxyuridine phosphonate analogue 5a. 
Reagents and conditions: (a) 1M TBAF in THF, rt, 3 h, 69%; (b) TMSBr, CH2Cl2, rt, 
overnight, 65%.  
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Figure 2. 2D ROESY (500.13 MHz, 298.0 K) spectrum of compound 1a 
 
 
 
  
 
 
Table 1. Antiviral activity and cytotoxicity of 5-modified 2’-deoxyuridine phosphonate 
analogues against different HCMV and VZV strains in HEL cell cultures.  
Compound 
EC50
a
 (μM)  Cytotoxicity (μM) 
HCMV 
AD-169 
HCMV 
Davis 
VZV 
OKA 
VZV 
(TK
-
) 
07/1 
 Cell 
morphology
b
 
(MCC) 
Cell 
growth
c
 
(CC50) 
1a > 100 > 100 > 100 > 100 
 
> 100  
2a 45 45 100 100 
 
> 100 > 100 
3a > 20 41 > 20 > 20 
 
≥ 100 > 100 
4a 55 63 > 100 > 100 
 
> 100 100 
1b > 100 > 100 > 100 > 100 
 
> 100  
2b 45 > 20 100 100 
 
≥ 100 > 100 
3b > 100 > 100 > 100 > 100 
 
> 100  
4b > 100 > 100 > 100 > 100 
 
> 100  
        
Acyclovir   1.3 37 
 
> 440  
Brivudin   0.026 12 
 
> 300  
        
Ganciclovir 7.9 7.0   
 
≥ 394 141 
Cidofovir 0.67 0.95   
 
≥ 317 63 
aEffective concentration required to reduce virus-induced cytopathicity by 50%. Virus input was 100 plaque forming 
units (PFU). 
bMinimum cytotoxic concentration or compound concentration that caused a microscopically detectable alteration of 
cell morphology. 
c50%-Cytotoxic concentration or compound concentration required to reduce cell growth by 50%. 
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